Adverse effects may indicate drug efficacy. Therefore, discontinuation should be discussed carefully. As has reinstitution of treatment. For review of pulmonary and nonpulmonary AEs, see under PMID 26371282, 27532025. Guidelines are available at manufacturers' websites
Last update : 25/10/2016